Sixth blood pressure medication recalled over carcinogen concerns

EAST WINDSOR, N.J. – Another blood pressure medication has been recalled over concerns it could contain trace amounts of carcinogens. 

The medication is manufactured by Aurobino Pharma USA, Inc. The recall is voluntary.

It affects 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP.

If you take the drug, contact your doctor.

You can check out all the latest drug recalls here.

Six blood pressure medications have been recalled since November.

All have been found to have trace amounts of N-nitrosodiethylamine (NDEA) and are manufactured by different companies.

The blood pressure medications still under recall according to the FDA: Aurobindo (Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP), Mylan (Valsartan-containing products), Teva Pharmaceuticals (Amlodipine/Valsartan Combination Tables and Amlopidine/Valsartan/Hydrochlorothiazide Combination Tablets), Mylan (Amlodipine and Valsartan Tablets; Valsartan Tablets; Valsartan and Hydrochlorothiazide Tablets), Torrent Pharmaceuticals Limited (Losartan potassium tablets, USP).

To learn more from the FDA, click here.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.